AU2008308657A1 - Sustained delivery of compstatin analogs from gels - Google Patents

Sustained delivery of compstatin analogs from gels Download PDF

Info

Publication number
AU2008308657A1
AU2008308657A1 AU2008308657A AU2008308657A AU2008308657A1 AU 2008308657 A1 AU2008308657 A1 AU 2008308657A1 AU 2008308657 A AU2008308657 A AU 2008308657A AU 2008308657 A AU2008308657 A AU 2008308657A AU 2008308657 A1 AU2008308657 A1 AU 2008308657A1
Authority
AU
Australia
Prior art keywords
compstatin analog
liquid composition
compstatin
composition
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008308657A
Other languages
English (en)
Inventor
Pascal Deschatelets
Cedric Francois
Paul Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Publication of AU2008308657A1 publication Critical patent/AU2008308657A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2008308657A 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels Abandoned AU2008308657A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US60/976,919 2007-10-02
US2646008P 2008-02-05 2008-02-05
US61/026,460 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200626 Division 2008-10-02

Publications (1)

Publication Number Publication Date
AU2008308657A1 true AU2008308657A1 (en) 2009-04-09

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008308657A Abandoned AU2008308657A1 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Country Status (12)

Country Link
US (1) US20110182877A1 (enExample)
EP (1) EP2207530A4 (enExample)
JP (1) JP2010540654A (enExample)
KR (2) KR20150080007A (enExample)
CN (1) CN101854916A (enExample)
AU (1) AU2008308657A1 (enExample)
BR (1) BRPI0817524A2 (enExample)
CA (1) CA2701470A1 (enExample)
MX (1) MX2010003630A (enExample)
RU (1) RU2505311C2 (enExample)
WO (1) WO2009046198A2 (enExample)
ZA (1) ZA201002365B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
PT2425814E (pt) 2010-09-03 2013-09-02 Novagali Pharma Sa Emulsão de tipo água em óleo para tratamento de uma doença ocular
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
ES2524580T3 (es) 2010-09-03 2014-12-10 Santen Sas Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
CN107050422B (zh) 2011-05-11 2021-11-09 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
US20160067357A1 (en) * 2012-08-17 2016-03-10 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
CA2891673C (en) 2012-11-15 2025-10-07 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
JP6968787B2 (ja) * 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP2311480B1 (en) * 2002-09-20 2013-06-26 The Trustees of The University of Pennsylvania Compstatin analogs with improved activity
JP5345849B2 (ja) * 2005-10-08 2013-11-20 ポテンシア ファーマシューティカルズ， インコーポレイテッド 眼の障害のためのコンプスタチンおよびそのアナログ
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP1960422B1 (en) * 2005-11-28 2012-05-30 The Trustees of The University of Pennsylvania Potent compstatin analogs
US20070149616A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
EP2148691B1 (en) * 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system

Also Published As

Publication number Publication date
EP2207530A4 (en) 2013-09-11
JP2010540654A (ja) 2010-12-24
WO2009046198A3 (en) 2009-07-16
KR20150080007A (ko) 2015-07-08
US20110182877A1 (en) 2011-07-28
EP2207530A2 (en) 2010-07-21
KR20100094453A (ko) 2010-08-26
RU2010113513A (ru) 2011-11-10
BRPI0817524A2 (pt) 2017-05-02
CN101854916A (zh) 2010-10-06
MX2010003630A (es) 2010-04-21
WO2009046198A2 (en) 2009-04-09
ZA201002365B (en) 2010-12-29
CA2701470A1 (en) 2009-04-09
RU2505311C2 (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
US20110182877A1 (en) Sustained delivery of compstatin analogs from gels
AU2006302212B2 (en) Compstatin and analogs thereof for eye disorders
US10407466B2 (en) Methods of selecting compstatin mimetics
US20090117171A1 (en) Compositions and methods for treatment of macular degeneration and related conditions
AU2016253654A1 (en) Injectable combination therapy for eye disorders
HK1121380A (en) Compstatin and analogs thereof for eye disorders
HK1121380B (en) Compstatin and analogs thereof for eye disorders
TW202214285A (zh) 治療眼病之方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application